Literature DB >> 9187444

Hodgkin's disease: complications of therapy and excess mortality.

R T Hoppe1.   

Abstract

BACKGROUND: The long-term survival of patients treated for Hodgkin's disease permits careful evaluation of long-term complications and excess mortality. PATIENTS AND METHODS: Between 1960 and 1995, 2498 patients who were treated for Hodgkin's disease at Stanford University were evaluated. Survival, freedom from relapse, and important complications of therapy (cardiac disease and secondary cancers) were analyzed, and risk of mortality from all causes was calculated utilizing absolute excess risk calculations.
RESULTS: The risk of death from Hodgkin's disease is 17% at 15 years of follow-up and increases only slightly thereafter. The risk of death from other causes is also 17% at 15 years, but increases sharply thereafter. The major causes of mortality (other than Hodgkin's disease) are secondary cancers and cardiac disease. Second cancers with significant increase in risk include leukemia (acute nonlymphocytic), non-Hodgkin's lymphoma, lung/pleural cancer, breast cancer, melanoma, soft tissue and bone sarcomas, stomach cancer, salivary gland tumors, thyroid cancer, and pancreatic cancer. The absolute excess risk of death from causes other than Hodgkin's disease increases during each five-year follow-up interval for at least 25 years. However, the absolute excess risk of death during similar follow-up periods is less for patients treated in more recent years (1980-1995) than in the prior treatment era (1962-1980).
CONCLUSIONS: Mortality for causes other than Hodgkin's disease is important in the long-term follow-up of patients. Causes of death are often treatment related. Changes in treatment programs can reduce the long-term excess risk of death from complications of therapy.

Entities:  

Mesh:

Year:  1997        PMID: 9187444

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  25 in total

Review 1.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

Review 2.  Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis.

Authors:  Ezzeldin M Ibrahim; Ghieth A Kazkaz; Khaled M Abouelkhair; Mubarak M Al-Mansour; Turki M Al-Fayea; Meteb Al-Foheidi; Ali M Bayer; Osama A Elmasri
Journal:  Lung       Date:  2012-10-06       Impact factor: 2.584

Review 3.  Late complications after treatment for Hodgkin lymphoma.

Authors:  Andrea K Ng
Journal:  Curr Hematol Malig Rep       Date:  2008-07       Impact factor: 3.952

4.  Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.

Authors:  Michael Zach Koontz; Sandra J Horning; Raymond Balise; Peter L Greenberg; Saul A Rosenberg; Richard T Hoppe; Ranjana H Advani
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

Review 5.  Second malignancies among elderly survivors of cancer.

Authors:  Ari M VanderWalde; Arti Hurria
Journal:  Oncologist       Date:  2011-10-31

6.  Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Authors:  Ana C Xavier; Narendranath Epperla; Jeffrey W Taub; Luciano J Costa
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

7.  Cost effectiveness and screening interval of lipid screening in Hodgkin's lymphoma survivors.

Authors:  Aileen B Chen; Rinaa S Punglia; Karen M Kuntz; Peter M Mauch; Andrea K Ng
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

8.  Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.

Authors:  Sara Aquino; Marino Clavio; Edoardo Rossi; Luana Vignolo; Maurizio Miglino; Mauro Spriano; Letizia Canepa; Gioacchino Catania; Ivana Pierri; Micaela Bergamaschi; Roberta Gonella; Carlo Marani; Omar Racchi; Marina Cavaliere; Riccardo Goretti; Federico Carbone; Andrea Bruzzone; Rodolfo Tassara; Angelo Michele Carella; Riccardo Ghio; Marco Gobbi
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

9.  Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease.

Authors:  Swati K Basu; Cindy Schwartz; Susan G Fisher; Melissa M Hudson; Nancy Tarbell; Ann Muhs; Karen J Marcus; Nancy Mendenhall; Peter Mauch; Larry E Kun; Louis S Constine
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-01       Impact factor: 7.038

10.  Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study.

Authors:  P Youn; H Li; M T Milano; M Stovall; L S Constine; L B Travis
Journal:  Ann Oncol       Date:  2012-07-31       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.